Steven H. Stein
Executive VP, Head of Late-stage Development & Chief Medical OfficerDr. Steven H. Stein, M.D. is Director of Alpha-9 Theranostics, Inc. Dr. Steven H. Stein, serves as an Independent Director of Repare Therapeutics Inc. since June 17, 2024. He served as an Independent Director of Theseus Pharmaceuticals, Inc. since October 2022 until February 14, 2024. He is Chief Medical Officer at Incyte Corporation since March 2015. He has been Executive Vice President of Incyte Corporation since May 2016 and is its Head of Late-stage Development and served as its Senior Vice President since March 2015. Dr. Stein's primary responsibility at Novartis was leading Novartis Oncology's North American medical/scientific activities, including the planning, resource allocation and execution of registration and non-registration studies. He was also responsible for the Medical Sciences & Health Outcomes function, which included the Scientific Communications, Medical Information and Health Economics and Outcomes Research groups. Prior to joining Incyte, from May 2011 to February 2015, he was the Senior Vice President of US Clinical Development & Medical Affairs at Novartis Oncology U. S. Novartis Pharmaceuticals. From February 2004 to April 2011, Dr. Stein was the Vice President, Global Oncology, Clinical Development and the Head of Medicines Development for Hematology and Supportive Care for GlaxoSmithKline. Dr. Stein had been an Independent Director at Kura Oncology, Inc. since January 3, 2017 until 2023. He had authored more than 100 scientific papers and presentations and was also an active Member of several professional and scientific societies and academic committees. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the School of Medicine, University of Pennsylvania. Dr. Stein earned his MD from the University of Witwatersrand in Johannesburg, South Africa in 1990. Dr. Stein held a post-doctoral fellowship in hematology/oncology at the University of Pennsylvania from 1998 to 2001.
Positions
- Company NameIncyte CorporationStock CodeINCYPositionExecutive VP, Head of Late-stage Development & Chief Medical OfficerColleagues
- WJWilliam J. MeuryCEO & Director
- JCJulian Charles BakerIndependent Chairman of the Board
- PJPablo J. CagnoniPresident and Global Head of R&D
- TTThomas TrayPrincipal Financial Officer, VP of Finance & Chief Accounting Officer
- MKMohamed Khairie IssaExecutive Vice President & Head of U.S. Commercial
- JBJean-Jacques BienaimeIndependent Director
- PJPaul J. ClancyIndependent Director
- JAJacqualyn A. FouseIndependent Director
